All In Biotech

Drug Trial Radar · NCT04713358

Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia

Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 542 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

542

Actual

Start

Sep 24, 2021

Primary completion

Dec 31, 2023

Study completion Dec 31, 2023

Sponsor

Lead sponsor
RenJi HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Tong Ren Hospital; First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Zhengzhou University
First posted
Jan 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Postoperative recovery is an important part of the patient's experience. A good recovery period is an important guarantee for the recovery of postoperative organs and functions after surgery. However, the delay in awakening after general anesthesia remains one of the biggest challenges facing anesthesiologists. The time of resuscitation depends on patient factors, effects of anesthetic factors, duration of surgery, and painful stimulation. The delay of recovery after anesthesia was mainly caused by the use of anesthetic drugs during the perioperative period. The drugs commonly used during the perioperative period are opioid analgesics, sedatives and muscle relaxants. Studies have shown that intravenous opioids are more difficult to control than neuromuscular relaxants. Opioids can extend the recovery time after anesthesia by direct sedation of opioid receptors. It also reduces the sensitivity of brainstem chemoreceptors to carbon dioxide, leading to dose-dependent respiratory depression and hypercapnia, which affects the removal of volatile substances and carbon dioxide, and ultimately leads to coma. In addition, the active metabolites of some opioids can prolong the duration of action, especially in the case of impaired renal function, which can lead to delayed awakening. As an opioid antagonist, nalmefene can inhibit or reverse the respiratory inhibition, sedation and hypotension effects of opioid drugs. Moreover, it has no opioid excitatory activity, does not produce respiratory inhibition, hallucinogenic effect or pupil dilation. In terms of inducing wakefulness during anesthesia, nalmefene can effectively reverse the sedative effect caused by opioids. There have been reports at home and abroad that nalmefene can be used to improve the effect of post-anesthesia resuscitation and reduce agitation during the waking period, but there is still a lack of large sample and well-designed randomized controlled studies to provide important data on how to improve the quality of anesthetized resuscitation. This study will conduct a rigorous randomized controlled studies,with large sample, and the research indicators for patients from the PACU roll-out to ordinary ward, using Aldrete score , in order to obtain a series of data of nalmefene used for anesthesia recovery , and to set the foundation of related research of nalmefene and similar drugs in clinical application in the future.

Conditions

  • Resuscitation

Interventions

  • NalmefeneDrug

    Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery

  • normal SalineDrug

    Immediately Intravenous injection of normal saline 1ml after surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time stay in PACUTime frame: From the end of the operation to the time that patient leave to inpatient ward up to 2hours

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangxi Medical University

    Guangxi, Guangxi, China

  • Shanghai Tong Ren Hospital

    Shanghai, Shanghai Municipality, China

  • Renji Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Zhengzhou University

    Henan, Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.